Pharmabiz
 

DSM Anti-Infectives sets up facility at Punjab

Our Bureau, BangaloreFriday, July 24, 2009, 08:00 Hrs  [IST]

DSM Anti-Infectives has opened a facility at Toansa in Punjab for the production of Ampicillin. The company has implemented a novel enzymatic process for production of the Active Pharmaceutical Ingredient (API) which will help generate less waste compared to the conventional processes. Since this is an innovative application, the company has branded the Ampicillin API as Puricillin which comes under the umbrella of products Pure Actives. The product is being produced utilizing an eco-friendly enzymatic process using no organic solvents. DSM in India is a wholly-owned subsidiary of the parent company based in Netherlands. The new facility will cater to orders of the Asia Pacific region, Middle- East and African countries, in addition to the Indian market. According to Stefan Doboczky, president, DSM Anti-Infectives said that the company is looking at a long-term commitment in the emerging markets and India in particular. It plans to further build a sustainable manufacturing base in India. The multimillion dollars investment is a logical consequence of the other substantial investments we have already made in India. Further specific financials were not provided. Bharath Sesha, vice-president, DSM Anti-Infectives Asia, Middle East and Africa (AMEA) region said, "We are proud to bring this advanced green production technology in the industry for the production of Ampicillin in India will see us having a strong base in Asia, Middle East and Africa (AMEA) region." With the new DSM Anti-Infectives plant at Toansa the Group expands also the capacity for the production of Purimox, enzymatic Amoxicillin, one of the most important API for human and animal health. The high purity of Purimox benefiting both patients and customers and similar to Puricilin produced without utilizing solvents has since its introduction in 2006 set the standard in the market for this API. DSM has annual net sales of Euro 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. The company is the world's leading supplier of active pharmaceutical ingredients like Amoxicillin, Ampicillin, Cephalexin and Cefadroxil; which are widely used broad spectrum antibiotics for combating bacterial infections. With its enzymatic production technology for these API's the group has a unique position in serving its customers and via them patients with high quality products produced via environmentally friendly production routes.

 
[Close]